Xenon Pharmaceuticals (XENE) Reports Q1 Loss of $0.42, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Xenon Pharmaceuticals (XENE) Reports Q1 Loss of $0.42, Revenues Miss

Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 11, 2021 4:01 PM EDT

Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial Anticipated by End of Third Quarter of 2021

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make excellent progress across both our proprietary and partnered... More